sorafenib has been researched along with oxidopamine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | sorafenib (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caldwell, GA; Caldwell, KA; Dawson, TM; Dawson, VL; Hamamichi, S; Lee, BD; Liu, Z; Ray, A; Smith, WW; Yang, D | 1 |
1 other study(ies) available for sorafenib and oxidopamine
| Article | Year |
|---|---|
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Drosophila; Enzyme Activation; Humans; Indoles; Motor Activity; Mutation; Niacinamide; Oxidopamine; Parkinson Disease; Phenols; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Sorafenib; Synucleins | 2011 |